JumonjiC demethylase inhibitors show potential for targeting chemotherapy-resistant lung cancers

Abstract

Resistance to standard taxane-platin chemotherapy and tumor relapse are a major challenge in the treatment of non-small cell lung cancers (NSCLC). Our recent study identified JumonjiC demethylase inhibitors as a highly potent therapeutic strategy for targeting chemoresistant tumors and for preventing the emergence of drug-tolerant clones from taxane-platin treated NSCLCs.

Keywords

• drug resistance
• jmjc demethylases
• jumonji inhibitors
• kdm
• non-small cell lung cancer
• standard chemotherapy
• taxane-platin